芯源微(688037.SH)簽署投資協議 擬建設臨港研發及產業化項目
格隆匯1月15日丨芯源微(688037.SH)公佈,為提升高端半導體設備國產化步伐,完善公司的產業鏈佈局,提高半導體設備的設計、製造能力,公司擬與中國(上海)自由貿易試驗區臨港新片區管理委員會(以下簡稱“臨港新片區管委會”)、上海閔聯臨港聯合發展有限公司簽署《項目投資協議》,建設芯源微臨港研發及產業化項目。
公司擬在中國(上海)自由貿易試驗區臨港新片區競拍土地建設該項目。本次投資涉及的項目土地使用權的取得需要通過掛牌出讓方式進行,土地使用權能否競得、土地使用權的最終成交價格及取得時間存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.